Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year
- Revenue increased 18% year-over-year to $8.9 million
- Net loss decreased by 8% to $1.18 million from $1.28 million
- Successfully launched 6 new generic prescription drugs
- Gross profit improved to $2.73 million from $2.35 million
- Operating at a net loss of $1.18 million
- G&A expenses increased by 8.7% to $4.03 million
- G&A expenses significantly exceed gross profit, indicating operational inefficiency
Insights
Sunshine Biopharma shows improved revenue growth but remains unprofitable with concerning margin trends despite pipeline expansion.
Sunshine Biopharma's Q1 2025 results reveal mixed signals for investors. While the 18% revenue growth to
Looking deeper at the financials, there are concerning trends beneath the headline growth. Gross profit increased by only
The net loss decreased marginally by
On the operational front, the launch of six new generic prescription drugs across antibiotics, gastrointestinal disorders, and schizophrenia treatments demonstrates portfolio diversification efforts. This expanded product lineup likely contributed to revenue growth and represents potential for continued sales expansion in future quarters.
The appointment of Michel Roy as Chief Commercial Officer signals the company's focus on improving commercial performance. Meanwhile, progress with their K1.1 mRNA Lipid Nanoparticle product for hepatocellular carcinoma represents longer-term value potential, though commercialization timelines remain unclear. This preclinical advancement offers a glimpse of pipeline development beyond their current generic portfolio.
FORT LAUDERDALE, FL / / May 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has filed its 2025 first quarter report on Form 10-Q on Thursday, May 15, 2025. The following are highlights of the report:
Revenues in first quarter of 2025 were
$8.9 million , up18% over revenue of the same period last year.
Appointed a new Chief Commercial Officer, Mr. Michel Roy, a leader in the pharma industry.
Launched 6 new generic prescription drugs including two antibiotics, two drugs for gastrointestinal disorders and two drugs for schizophrenia.
Completed additional studies on orthotopic human tumor models in mice further confirming the Company's K1.1 mRNA Lipid Nanoparticle product as a novel therapeutic agent for human hepatocellular carcinoma.
"We are thrilled to report strong financial results for the first quarter of 2025, with an
The following are key elements of the Income Statement contained in the Company's 2025 first quarter report:
2025Q1 | 2024Q1 | |||||||
Revenue | $ | 8,901,341 | $ | 7,541,046 | ||||
Gross Profit | $ | 2,730,426 | $ | 2,354,337 | ||||
General & Administrative Expenses | $ | 4,026,176 | $ | 3,704,926 | ||||
Net Loss | $ | 1,179,771 | $ | 1,283,801 | ||||
About Sunshine Biopharma Inc.
Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG庐, a biosimilar of NEULASTA庐. Like NEULASTA庐, NIOPEG庐 is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: .
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For more information, please contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]
SOURCE: Sunshine Biopharma Inc.
View the original on ACCESS Newswire
FAQ
What was Sunshine Biopharma's (SBFM) revenue in Q1 2025?
How many new generic drugs did SBFM launch in Q1 2025?
What was Sunshine Biopharma's (SBFM) net loss in Q1 2025?
Who is the new Chief Commercial Officer of Sunshine Biopharma?
What progress did SBFM make in cancer research during Q1 2025?
